• Human GFRAL/GFR alpha-like protein (Recombinant) (C-His-Avi) {Biotin} (STJP001540)
  • Human GFRAL/GFR alpha-like protein (Recombinant) (C-His-Avi) {Biotin} (STJP001540)

Human GFRAL/GFR alpha-like protein (Recombinant) (C-His-Avi) {Biotin} (STJP001540)

SKU:
STJP001540

Shipping:
Free Shipping
Current Stock:
Host: HEK293
Note: STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human GFRAL/GFR alpha-like-C-His-Avi protein was developed from hek293 and has a target region of C-His-Avi. For use in research applications.
Conjugation: Biotin
Formulation: Lyophilised from 0.2 µm filtered PBS solution pH7.4.
Dilution Range: Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM
Storage Instruction: The lyophilized protein is stable for at least 1 year from date of receipt at-20°C.
Endotoxin: Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg).
Gene Symbol: GFRAL
Gene ID: 389400
Uniprot ID: GFRAL_HUMAN
Immunogen Region: Ser19-Glu351
Immunogen: DNA sequence encoding Human GFRAL/GFR alpha-like including a C-His-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology.
Function Brainstem-restricted receptor for GDF15 which regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses. Upon interaction with its ligand, GDF15, interacts with RET and induces cellular signaling through activation of MAPK- and AKT- signaling pathways.
Protein Name Gdnf Family Receptor Alpha-Like
Cellular Localisation Cell Membrane
Single-Pass Membrane Protein
Extracellular Side
Alternative Protein Names Gdnf Family Receptor Alpha-Like protein
GFRAL protein
C6orf144 protein
UNQ9356 protein
PRO34128 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance